PALB2 is altered in 1.41% of prostate carcinoma patients with PALB2 Mutation present in 1.11% of all prostate carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 20 clinical trials for prostate carcinoma, of which 17 are open and 3 are closed. Of the trials that contain PALB2 Mutation and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 12 are phase 2 (11 open), and 1 is phase 3 (1 open) [5].

Olaparib has evidence of efficacy in patients with PALB2 Mutation in prostate carcinoma [5].

PALB2 is altered in 1.99% of malignant solid tumor patients with PALB2 Mutation present in 1.66% of all malignant solid tumor patients [4].

PALB2 Mutation is an inclusion criterion in 33 clinical trials for malignant solid tumor, of which 28 are open and 5 are closed. Of the trials that contain PALB2 Mutation and malignant solid tumor as inclusion criteria, 13 are phase 1 (11 open), 8 are phase 1/phase 2 (5 open), and 12 are phase 2 (12 open) [5].

PALB2 is altered in 1.83% of breast carcinoma patients with PALB2 Mutation present in 1.28% of all breast carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 23 clinical trials for breast carcinoma, of which 19 are open and 4 are closed. Of the trials that contain PALB2 Mutation and breast carcinoma as inclusion criteria, 5 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 12 are phase 2 (10 open), and 2 are phase 3 (2 open) [5].

PALB2 is altered in 1.45% of ovarian carcinoma patients with PALB2 Mutation present in 1.19% of all ovarian carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 19 clinical trials for ovarian carcinoma, of which 15 are open and 4 are closed. Of the trials that contain PALB2 Mutation and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 8 are phase 2 (7 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

PALB2 is altered in 1.43% of prostate adenocarcinoma patients with PALB2 Mutation present in 1.12% of all prostate adenocarcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain PALB2 Mutation and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [5].

PALB2 Mutation is an inclusion criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain PALB2 Mutation and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

PALB2 Mutation is an inclusion criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain PALB2 Mutation and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

PALB2 is altered in 2.8% of adenocarcinoma of the gastroesophageal junction patients with PALB2 Mutation present in 2.49% of all adenocarcinoma of the gastroesophageal junction patients [4].

PALB2 Mutation is an inclusion criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain PALB2 Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [5].

PALB2 is altered in 1.29% of pancreatic adenocarcinoma patients with PALB2 Mutation present in 0.95% of all pancreatic adenocarcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 8 clinical trials for pancreatic adenocarcinoma, of which 7 are open and 1 is closed. Of the trials that contain PALB2 Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (6 open) [5].

PALB2 is altered in 1.29% of pancreatic carcinoma patients with PALB2 Mutation present in 0.97% of all pancreatic carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 7 clinical trials for pancreatic carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PALB2 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [5].

PALB2 is altered in 1.8% of non-small cell lung carcinoma patients with PALB2 Mutation present in 1.57% of all non-small cell lung carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 6 clinical trials for non-small cell lung carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PALB2 Mutation and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

PALB2 is altered in 3.49% of urothelial carcinoma patients with PALB2 Mutation present in 3.05% of all urothelial carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 5 clinical trials for urothelial carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PALB2 Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

PALB2 is altered in 2.91% of small cell lung carcinoma patients with PALB2 Mutation present in 1.57% of all small cell lung carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PALB2 Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [5].

PALB2 is altered in 1.5% of gastric carcinoma patients with PALB2 Mutation present in 1.37% of all gastric carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PALB2 Mutation and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

PALB2 is altered in 4.49% of endometrial carcinoma patients with PALB2 Mutation present in 3.66% of all endometrial carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PALB2 Mutation and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

PALB2 is altered in 3.72% of melanoma patients with PALB2 Mutation present in 3.48% of all melanoma patients [4].

PALB2 Mutation is an inclusion criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain PALB2 Mutation and melanoma as inclusion criteria, 4 are phase 2 (4 open) [5].

PALB2 is altered in 2.82% of colorectal carcinoma patients with PALB2 Mutation present in 2.33% of all colorectal carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PALB2 Mutation and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.51% of gastric adenocarcinoma patients with PALB2 Mutation present in 1.39% of all gastric adenocarcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain PALB2 Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [5].

PALB2 is altered in 0.85% of soft tissue sarcoma patients with PALB2 Mutation present in 0.65% of all soft tissue sarcoma patients [4].

PALB2 Mutation is an inclusion criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain PALB2 Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

PALB2 is altered in 0.48% of cervical carcinoma patients with PALB2 Mutation present in 0.48% of all cervical carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PALB2 Mutation and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.51% of head and neck carcinoma patients with PALB2 Mutation present in 1.06% of all head and neck carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 3 clinical trials for head and neck carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PALB2 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

PALB2 is altered in 1.29% of high grade ovarian serous adenocarcinoma patients with PALB2 Mutation present in 1.0% of all high grade ovarian serous adenocarcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain PALB2 Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

PALB2 is altered in 3.35% of bladder urothelial carcinoma patients with PALB2 Mutation present in 2.88% of all bladder urothelial carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 Mutation and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

PALB2 is altered in 3.23% of bladder carcinoma patients with PALB2 Mutation present in 2.79% of all bladder carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 Mutation and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

PALB2 is altered in 1.85% of esophageal carcinoma patients with PALB2 Mutation present in 1.85% of all esophageal carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 Mutation and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

PALB2 is altered in 1.69% of esophageal adenocarcinoma patients with PALB2 Mutation present in 1.69% of all esophageal adenocarcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 Mutation and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.49% of clear cell renal cell carcinoma patients with PALB2 Mutation present in 1.49% of all clear cell renal cell carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 Mutation and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

PALB2 is altered in 2.05% of head and neck squamous cell carcinoma patients with PALB2 Mutation present in 1.4% of all head and neck squamous cell carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

PALB2 is altered in 1.19% of non-hodgkin lymphoma patients with PALB2 Mutation present in 0.99% of all non-hodgkin lymphoma patients [4].

PALB2 Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

PALB2 is altered in 1.28% of squamous cell lung carcinoma patients with PALB2 Mutation present in 0.96% of all squamous cell lung carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [5].

PALB2 is altered in 0.79% of osteosarcoma patients with PALB2 Mutation present in 0.79% of all osteosarcoma patients [4].

PALB2 Mutation is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 Mutation and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

PALB2 is altered in 0.71% of gastrointestinal stromal tumor patients with PALB2 Mutation present in 0.56% of all gastrointestinal stromal tumor patients [4].

PALB2 Mutation is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain PALB2 Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PALB2 Mutation is an inclusion criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

PALB2 is altered in 14.29% of vaginal carcinoma patients with PALB2 Mutation present in 14.29% of all vaginal carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PALB2 Mutation and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PALB2 is altered in 4.35% of penile carcinoma patients with PALB2 Mutation present in 4.35% of all penile carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PALB2 Mutation and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PALB2 is altered in 4.19% of anal carcinoma patients with PALB2 Mutation present in 4.19% of all anal carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PALB2 Mutation and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PALB2 is altered in 3.31% of esophageal squamous cell carcinoma patients with PALB2 Mutation present in 3.31% of all esophageal squamous cell carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 3.22% of malignant uterine neoplasm patients with PALB2 Mutation present in 2.6% of all malignant uterine neoplasm patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 2.81% of colorectal adenocarcinoma patients with PALB2 Mutation present in 2.33% of all colorectal adenocarcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PALB2 is altered in 2.76% of malignant intestinal neoplasm patients with PALB2 Mutation present in 2.27% of all malignant intestinal neoplasm patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PALB2 is altered in 1.9% of multiple myeloma patients with PALB2 Mutation present in 1.9% of all multiple myeloma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.86% of medulloblastoma patients with PALB2 Mutation present in 1.86% of all medulloblastoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 is altered in 1.83% of malignant esophagogastric neoplasm patients with PALB2 Mutation present in 1.7% of all malignant esophagogastric neoplasm patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PALB2 is altered in 1.69% of mantle cell lymphoma patients with PALB2 Mutation present in 1.69% of all mantle cell lymphoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 is altered in 1.78% of glioma patients with PALB2 Mutation present in 1.59% of all glioma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 is altered in 1.89% of cancer patients with PALB2 Mutation present in 1.58% of all cancer patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and cancer as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.84% of lung carcinoma patients with PALB2 Mutation present in 1.56% of all lung carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.93% of diffuse large B-cell lymphoma patients with PALB2 Mutation present in 1.54% of all diffuse large B-cell lymphoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 is altered in 1.7% of malignant central nervous system neoplasm patients with PALB2 Mutation present in 1.52% of all malignant central nervous system neoplasm patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 is altered in 1.67% of malignant ovarian epithelial tumor patients with PALB2 Mutation present in 1.4% of all malignant ovarian epithelial tumor patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PALB2 is altered in 1.39% of malignant mesothelioma patients with PALB2 Mutation present in 1.39% of all malignant mesothelioma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.5% of malignant gastric neoplasm patients with PALB2 Mutation present in 1.37% of all malignant gastric neoplasm patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PALB2 is altered in 1.88% of invasive breast carcinoma patients with PALB2 Mutation present in 1.32% of all invasive breast carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.32% of renal cell carcinoma patients with PALB2 Mutation present in 1.25% of all renal cell carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.18% of gallbladder carcinoma patients with PALB2 Mutation present in 1.18% of all gallbladder carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.31% of B-cell non-hodgkin lymphoma patients with PALB2 Mutation present in 1.04% of all B-cell non-hodgkin lymphoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.52% of biliary tract carcinoma patients with PALB2 Mutation present in 1.01% of all biliary tract carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.61% of bile duct adenocarcinoma patients with PALB2 Mutation present in 0.97% of all bile duct adenocarcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PALB2 is altered in 1.61% of bile duct carcinoma patients with PALB2 Mutation present in 0.97% of all bile duct carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 1.61% of cholangiocarcinoma patients with PALB2 Mutation present in 0.97% of all cholangiocarcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 0.88% of mature T-cell and NK-cell non-hodgkin lymphoma patients with PALB2 Mutation present in 0.88% of all mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 is altered in 0.66% of Ewing sarcoma patients with PALB2 Mutation present in 0.66% of all Ewing sarcoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 is altered in 0.64% of ampulla of vater carcinoma patients with PALB2 Mutation present in 0.64% of all ampulla of vater carcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PALB2 is altered in 0.55% of neuroblastoma patients with PALB2 Mutation present in 0.55% of all neuroblastoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 is altered in 0.55% of rhabdomyosarcoma patients with PALB2 Mutation present in 0.55% of all rhabdomyosarcoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 is altered in 0.9% of leiomyosarcoma patients with PALB2 Mutation present in 0.54% of all leiomyosarcoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 is altered in 0.54% of low grade ovarian serous adenocarcinoma patients with PALB2 Mutation present in 0.54% of all low grade ovarian serous adenocarcinoma patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 is altered in 0.88% of malignant small intestinal neoplasm patients with PALB2 Mutation present in 0.44% of all malignant small intestinal neoplasm patients [4].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 Mutation and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PALB2 Mutation is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PALB2 Mutation and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].